Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Roche Holding AG Basel American Depositary Shares (OP: RHHBY)
62.70 USD  +0.25 (+0.40%)
Streaming Delayed Price  /  Updated: 12:18 PM EDT, Jun 19, 2013  /  Add to My Watchlist      
View: Quote Chart Options News SEC Filings
Press releases about Roche Holding AG Basel American Depositary Shares
 
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Roche introduces cobas p 312 pre-analytical system as compact, front-end automation solution for sample management in US and Canada
June 27, 2012
System provides comprehensive sample management, helps improve workflow efficiency via very small footprint Read More
from PR Newswire
New Data From Phase III Study Showed That People With HER2-Positive Metastatic Breast Cancer Lived Longer With Genentech’s Perjeta
June 22, 2012
from Business Wire News Releases
Ventana takes Digital Pathology to a new level with the new VENTANA iScan HT Scanner
June 13, 2012
from PR Newswire
Orexigen and Roche Look to Take Advantage of Lucrative Anti-Obesity Drug Market
June 12, 2012
Five Star Equities Provides Stock Research on Orexigen and Roche Read More
from Marketwired News Releases
FDA Approves Perjeta (Pertuzumab) for People With HER2-Positive Metastatic Breast Cancer
June 08, 2012
from Business Wire News Releases
Roche submits TnT-hs assay to FDA for clearance on the cobas immunoassay and Elecsys analyzers
June 07, 2012
Roche High Sensitivity Troponin T assay would meet the diagnostic goals set by the Universal Definition of Myocardial Infarction (MI). The advantages of this test include improved analytical... Read More
from PR Newswire
Roche Diagnostics enters strategic alliance with med fusion that recognizes company as a Roche Molecular Center of Excellence
June 05, 2012
Collaborative relationship designed to help accelerate advancement of new methods in molecular diagnostics testing and personalized predictive treatment Read More
from PR Newswire
Genentech Data Showed That People With Metastatic Colorectal Cancer Lived Longer When They Continued on Avastin Plus Chemotherapy
June 03, 2012
from Business Wire News Releases
Genentech’s Targeted Investigational Breast Cancer Medicine, Trastuzumab Emtansine (T-DM1), Reduced the Risk of Cancer Worsening or Death by 35 Percent in Pivotal Phase III Trial
June 02, 2012
from Business Wire News Releases
Genentech Study Showed That Adding Avastin to Chemotherapy Cut the Risk of the Disease Getting Worse in Difficult-to-Treat Recurrent Ovarian Cancer by Half
June 02, 2012
from Business Wire News Releases
Ventana signs exclusive licensing agreement for the commercialization of a novel BRAF V600E mutation antibody for cancer detection
May 31, 2012
New assay will strengthen leadership in emerging area of mutation-specific antibodies to address unmet medical needs in cancer Read More
from PR Newswire
Ensemble Therapeutics and Genentech Initiate Collaboration to Discover Macrocyclic Drug Candidates
May 29, 2012
from Business Wire News Releases
Ventana licenses Gen-Probe IP for measuring ERG protein in prostate cancer patients
May 21, 2012
Emerging biomarker will enable novel clinical assays and Personalized Healthcare for prostate cancer Read More
from PR Newswire
ARUP Laboratories celebrates new state-of-the-art diagnostic technology with the VENTANA BenchMark Special Stains system
May 17, 2012
from PR Newswire
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
May 16, 2012
from Business Wire News Releases
Groundbreaking Alzheimer's Disease Prevention Trial Announced
May 15, 2012
Study of Novel Anti-Amyloid Therapy Will Help Launch New Research Era Read More
from PR Newswire
Array BioPharma and Genentech's Strategic Alliance Voted Breakthrough Alliance of 2012
May 14, 2012
from Business Wire News Releases
Anti-Obesity Drugs a Hot Topic in the Biotech Industry
May 14, 2012
The Paragon Report Provides Stock Research on VIVUS and Roche Read More
from Marketwired News Releases
Ventana Receives FDA Clearance for p53 (DO-7) Image Analysis and Digital Read Applications
May 07, 2012
from PR Newswire
Genentech Reports Positive Study of ACTEMRA Given by Subcutaneous Injection
May 03, 2012
from Business Wire News Releases
Lorus Therapeutics and Genentech Sign Global Intellectual Property License Agreement for IL-17E in Cancer
May 01, 2012
from Marketwired News Releases
Roche decides not to extend its tender offer for Illumina, Inc.
April 18, 2012
from Business Wire News Releases
Seattle Genetics and Millennium to Collaborate with Ventana on Companion Diagnostic for ADCETRIS™ in CD30-Positive Malignancies
April 12, 2012
from Business Wire News Releases
Roche issues statement regarding Illumina offer
April 12, 2012
from Business Wire News Releases
Roche sends open letter to Illumina shareholders
April 11, 2012
from Business Wire News Releases
Monster OTC: Breaking News, Roche (RHHBY) Interested in GALE's NeuVax
April 07, 2012
from EmailWire.Com Press Releases
Roche disappointed with ISS recommendation
April 06, 2012
from Business Wire News Releases
Roche sends second letter to Illumina shareholders
April 04, 2012
from Business Wire News Releases
Roche disappointed by Illumina, Inc.’s Board of Directors’ rejection
April 03, 2012
from Business Wire News Releases
Roche Receives FDA Approval for cobas p 630 Pre-analytical Solution for Automated Molecular Testing Platform
March 30, 2012
New instrument, software integrate automated primary tube handling with fully automated platform for sample preparation, amplification and detection Read More
from PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here